z-logo
open-access-imgOpen Access
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
Author(s) -
Paul T. Heath,
Eva Galiza,
D. N. Baxter,
Marta Boffito,
Duncan L. Browne,
Fiona Burns,
David Chadwick,
Rebecca A. Clark,
Catherine A. Cosgrove,
James Galloway,
Anna L. Goodman,
Amardeep Heer,
Andrew Higham,
Shalini Iyengar,
Christopher Jeanes,
Philip A. Kalra,
Christina Kyriakidou,
Judy Bradley,
Chigomezgo Munthali,
Angela M. Minassian,
Fiona McGill,
Patrick Moore,
Imrozia Munsoor,
Helen Nicholls,
Orod Osanlou,
Jonathan Packham,
Carol Pretswell,
Alberto San Francisco Ramos,
Dinesh Saralaya,
Ray Sheridan,
Richard Smith,
Roy L. Soiza,
Pauline A. Swift,
Emma C. Thomson,
Jeremy Turner,
Marianne Elizabeth Viljoen,
Louis Fries,
Iksung Cho,
Irene McKnight,
Greg Glenn,
Elizabeth Rivers,
Andreana Robertson,
Katia Alves,
Kathy Smith,
Seth Toback
Publication year - 2022
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciac803
Subject(s) - medicine , placebo , asymptomatic , adverse effect , vaccination , randomized controlled trial , regimen , population , immunology , vaccine efficacy , pathology , alternative medicine , environmental health

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom